Jeff Engelman News Today

We asked investors to name the startups poised for success in a tough market, from young upstarts to companies on the brink of going public.

Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., will retire at the end of the year, following the lead of CEO Alex Gorsky, who also departs soon. Emile Nuwaysir led Bayer's $1 billion bet on Parkinson's disease, and now he heads up gene therapy biotech Ensoma. Genentech's early cancer research leader Shiva Malek jumps to Novartis' NIBR oncology unit.

The Novartis Institutes for BioMedical Research's oncology department has poached Genentech’s Shiva Malek, Ph.D., to help lead its cancer research.

Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.

by Kyle LaHucik | May 19, 2021 9:55am Another Novartis R&D leader exits the Swiss pharma giant to take on an executive role at a biotech startup. (Pixabay) Novartis Gopi Shanker, Ph.D., is the latest R&D leader to exit the Swiss pharma giant as he takes up the helm of chief scientific officer at gene therapy startup Tevard Biosciences.   Shanker follows the exit of Jeff Engelman M.D., Ph.D., who left the Novartis Institutes for Biomedical Research (NIBR) in late-Apr...

(Loxo Oncology) Josh Bilenker, M.D., and Jeff Engelman M.D., Ph.D., have joined forces to create a new cancer biotech, tapping their combined considerable experience to find new solutions to old oncology research problems. These are big names: Bilenker was until the start of the year Lilly’s cancer R&D chief, put in that position after the Big Pharma ponied up $8 billion for Bilenker’s startup Loxo Oncology two years back. It seems Bilenker wants to get back to biotech and is taki...